RxDoctor Payments Data

Paola Ponce

Family · Las Vegas, NVNPI 1083205736

Payments from drug & device makers

$5,806in general payments, 2019–2025

Across 76 payments — averaging $76.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Spinal Simplicity, LLC$1K
  • Medtronic$940
  • AbbVie$288
  • SPR Therapeutics, Inc$237
  • Lundbeck LLC$189
  • plus $579 from 8 others

What the payments were for

  • Travel & lodging$2,82349%
  • Food & beverage$2,93851%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific12$2,103
Spinal Simplicity, LLC12$1,470
Medtronic21$940
AbbVie10$288
SPR Therapeutics, Inc5$237
Lundbeck LLC4$189
Relievant Medsystems, Inc.1$171
GRT US Holding, Inc.1$130
Tonix Medicines, Inc.1$84
Stimwave Technologies Incorporated3$63
Averitas Pharma Inc.3$62
Pfizer1$26
Protega Pharmaceutials Inc1$22
Painteq LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,806 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$109,774
Medicare patients
183
Services billed
1,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl36$26,865
Xtampza ErOxycodone Myristate44$20,932
Oxymorphone Hcl ErOxymorphone Hcl13$13,108
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen204$8,880
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen270$7,647
Oxycodone Hcl269$6,668
Fentanyl23$3,981
Lidocaine43$2,936
Morphine Sulfate ErMorphine Sulfate109$2,394
Pregabalin88$1,566
Gabapentin116$1,443
Diclofenac Sodium29$1,388
ProgesteroneProgesterone, Micronized28$1,090
Cyclobenzaprine Hcl94$992
Tizanidine Hcl106$742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieArmour Thyroid$288$50213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →